Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 364

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells

Open access
Cordeiro, Ana, Bezerra, Evandro D., Hirayama, Alexandre V., Hill, Joshua A., Wu, Qian V., Voutsinas, Jenna, Sorror, Mohamed L., Turtle, Cameron J., Maloney, David G., Bar, Merav·2020·Biology of Blood and Marrow Transplantation

Abstract

CD19-targeted chimeric antigen receptor-modified T cell (CAR-T cell) therapy has shown excellent antitumor activity in patients with relapsed/refractory B cell malignancies, with very encouraging response rates and outcomes. However, the late effects following this therapy remain unknown. Here we report late adverse events-defined as starting or persisting beyond 90 days after CAR-T cell infusion-in patients who survived at least 1 year after therapy. The median duration of follow-up was 28.1 months (range, 12.5 to 62.6 months). At last follow-up, 73% of patients were still alive and 24% were in ongoing complete remission (CR). The most common late adverse event was hypogammaglobulinemia (IgG <400 mg/dL or i.v immunoglobulinm (IVIG) replacement, observed in 67% of the patients with available data. Infection density was .55 infection/100 days at risk (2.08 per patient-year). The majority (80%) of the infections were treated in the outpatient setting, and 5% necessitated admission to the intensive care unit (ICU). Subsequent malignancies occurred in 15% of patients, including 5% with myelodysplastic syndrome (MDS). Among patients with ongoing CR and with no MDS, 16% experienced prolonged cytopenia requiring transfusions or growth factor support. Graft-versus-host disease occurred in 3 of 15 patients (20%) who had undergone previous allogeneic hematopoietic cell transplantation. Most of the late events observed in this cohort were not severe, and many could be related to previous or subsequent therapies, suggesting a safe long-term profile of CD19-targeted CAR-T cell immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bbmt.2019.08.003

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 364

Metadata

Authors
Cordeiro, A., Bezerra, E. D., Hirayama, A. V., Hill, J. A., Wu, Q. V., Voutsinas, J., Sorror, M. L., Turtle, C. J., Maloney, D. G., & Bar, M.
Venue
Biology of Blood and Marrow Transplantation
Publisher
Elsevier BV
Published
2020-01
Volume
26
Issue
1
Pages
26-33
ISSN
1083-8791 (ISSN-L)
OpenAlex
W2967884832
Cited by
364
References
28
FWCI
13.15
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells. https://app.cochat.ai/papers/10.1016/j.bbmt.2019.08.003
The paper
Cordeiro, A., Bezerra, E. D., Hirayama, A. V., Hill, J. A., Wu, Q. V., Voutsinas, J., Sorror, M. L., Turtle, C. J., Maloney, D. G., & Bar, M. (2020). Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells. Biology of Blood and Marrow Transplantation. https://doi.org/10.1016/j.bbmt.2019.08.003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.